Mirae Asset Nifty 500 Healthcare ETF vs Nippon India Pharma Fund
Direct Plan where a fund has one, Growth option · Data as on 30-10-2026
Mirae Asset Nifty 500 Healthcare ETF is an ETF fund and Nippon India Pharma Fund is a Sectoral fund. Mirae Asset Nifty 500 Healthcare ETF charges 0.35% a year and Nippon India Pharma Fund 0.99%. Their portfolios overlap 61.2%: they hold 26 of the same securities.
Mirae Asset Nifty 500 Healthcare ETF
ETF
- Expense ratio
- 0.35%
- NAV
- ₹21.44
Which is better, Mirae Asset Nifty 500 Healthcare ETF or Nippon India Pharma? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Mirae Asset Nifty 500 Healthcare ETF costs less: 0.35% a year against 0.99%.
- Nippon India Pharma fell less in its worst fall since 11-02-2026: −9.6% against −9.6%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹15 Cr.
- Their portfolios overlap 61.2%: 26 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Mirae Asset Nifty 500 Healthcare ETF | Nippon India Pharma Fund |
|---|---|---|
| Fund house | Mirae Asset Mutual Fund | Nippon India Mutual Fund |
| Category | ETF | Sectoral |
| AUM | ₹15 Cr (30-09-2026) | ₹9,166 Cr (30-09-2026) |
| NAV | ₹21.44 | ₹625.46 (Direct) |
| Expense ratio (Direct) | Not available | 0.99% |
| Expense ratio (Regular) | Not available | 1.85% |
| Riskometer | Very High | Very High |
| Benchmark | Nifty500 Healthcare TRI | BSE Healthcare TRI |
| Launch date | Not available | 05-06-2004 |
| Minimum investment | On exchange in multiple of 1 unit. With AMC: In multiples of 5,000 units | ₹5,000 |
| Lock in | None | None |
| Fund managers | Ekta Gala, amp, Ritesh Patel | Sailesh Raj Bhan |
| Exit load | NIL | Exit load of 1% if redeemed within 1 month. |
Mirae Asset Nifty 500 Healthcare ETF vs Nippon India Pharma: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Mirae Asset Nifty 500 Healthcare ETF | +1.43% | −0.66% | +12.95% | -- | -- | -- | -- |
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
Category average: the average of the 20 Sectoral funds, same plan type.
Mirae Asset Nifty 500 Healthcare ETF vs Nippon India Pharma: Year-wise Returns
| Year | Mirae Asset Nifty 500 Healthcare ETFMirae Asset Nifty 500 Healthcare ETF | Nippon India PharmaNippon India Pharma |
|---|---|---|
| 2026to date | -- | +9.76% |
| 2025 | -- | −2.46% |
| 2024 | -- | +35.26% |
| 2023 | -- | +40.36% |
| 2022 | -- | −9.06% |
| 2021 | -- | +25.12% |
Mirae Asset Nifty 500 Healthcare ETF vs Nippon India Pharma: Rolling Returns
Every holding period of both funds, against Nifty500 Healthcare TRI, the benchmark of Mirae Asset Nifty 500 Healthcare ETF
Mirae Asset Nifty 500 Healthcare ETF vs Nippon India Pharma: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Mirae Asset Nifty 500 Healthcare ETF | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +23.46% | +17.18% |
| Standard deviation | 14.16% | 15.19% |
| Sharpe ratio | 1.29 | 0.73 |
| Sortino ratio | 1.90 | 1.06 |
| Maximum drawdown | −9.6% (23-10-2026) | −24.0% (29-05-2017) |
| Beta | 1.00 | 0.85 |
| Alpha | −0.22% | +3.72% |
From daily NAVs, 11-02-2026 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Mirae Asset Nifty 500 Healthcare ETF
Nippon India Pharma Fund (Direct)
Nifty500 Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Mirae Asset Nifty 500 Healthcare ETF | −9.6% | 23-09-2026 | 23-10-2026 | Not yet | -- | −3.0% |
| Nippon India Pharma Fund (Direct) | −9.6% | 31-08-2026 | 23-10-2026 | Not yet | -- | −4.3% |
| Nifty500 Healthcare TRI | −9.6% | 23-09-2026 | 23-10-2026 | Not yet | -- | −2.9% |
From daily values since 11-02-2026, the first day every fund has.
Mirae Asset Nifty 500 Healthcare ETF vs Nippon India Pharma: Portfolio Overlap
From each fund's latest monthly portfolio: Mirae Asset Nifty 500 Healthcare ETF, September 2026; Nippon India Pharma Fund, September 2026
Holdings in common
- Overlap
- 61.2%
- Held by both
- 26
- Only in Mirae Asset Nifty 500 Healthcare ETF
- 18
- Only in Nippon India Pharma
- 10
| Security | % of Mirae Asset Nifty 500 Healthcare ETF | % of Nippon India Pharma |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 10.13% | 11.71% |
| Divi's Laboratories Ltd. | 8.76% | 7.10% |
| Cipla Ltd. | 5.62% | 6.01% |
| Dr. Reddy's Laboratories Ltd. | 5.58% | 5.45% |
| Apollo Hospitals Enterprise Ltd. | 6.24% | 4.89% |
| Lupin Ltd. | 3.66% | 6.17% |
| Max Healthcare Institute Ltd. | 5.13% | 2.70% |
| Mankind Pharma Ltd. | 2.10% | 4.38% |
| IPCA Laboratories Ltd. | 1.98% | 2.87% |
| Alkem Laboratories Ltd. | 2.31% | 1.82% |
| Gland Pharma Ltd. | 1.71% | 2.53% |
| Aurobindo Pharma Ltd. | 3.43% | 1.65% |
| Sai Life Sciences Ltd. | 1.56% | 3.92% |
| Ajanta Pharma Ltd. | 1.22% | 3.61% |
| Dr. Lal Path labs Ltd. | 1.15% | 2.17% |
| Fortis Healthcare Ltd. | 2.98% | 1.13% |
| Abbott India Ltd. | 1.04% | 2.32% |
| Biocon Ltd. | 1.91% | 1.01% |
| Piramal Pharma Ltd. | 0.95% | 2.24% |
| Narayana Hrudayalaya Ltd. | 0.92% | 1.61% |
| Glaxosmithkline Pharmaceuticals Ltd. | 0.85% | 3.11% |
| Anthem Biosciences Ltd. | 0.69% | 1.19% |
| Emcure Pharmaceuticals Ltd. | 0.60% | 1.36% |
| Vijaya Diagnostic Centre Ltd. | 0.52% | 2.62% |
| Syngene International Ltd. | 0.51% | 1.40% |
| Concord Biotech Ltd. | 0.34% | 0.17% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 61.2% means 61.2% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Mirae Asset Nifty 500 Healthcare ETF
| Security | % of fund |
|---|---|
| Laurus Labs Ltd. | 5.72% |
| Torrent Pharmaceuticals Ltd. | 5.24% |
| Glenmark Pharmaceuticals Ltd. | 2.61% |
| Zydus Lifesciences Ltd. | 2.14% |
| Krishna Institute of Medical Sciences Ltd. | 1.48% |
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| MedPlus Health Services Limited | 2.53% |
| Thyrocare Technologies Limited | 2.24% |
| Suraksha Diagnostic Limited | 1.51% |
| Pfizer Limited | 1.35% |
| Akums Drugs and Pharmaceuticals Limited | 1.21% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Mirae Asset Nifty 500 Healthcare ETF | Nippon India Pharma |
|---|---|---|
| Equity | 100.0% | 97.3% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.0% | 2.7% |
Market cap of stocks
| Market cap | Mirae Asset Nifty 500 Healthcare ETF | Nippon India Pharma |
|---|---|---|
| Large Cap | 36.0% | 29.7% |
| Mid Cap | 45.6% | 39.0% |
| Small Cap | 18.3% | 28.0% |
| Not on AMFI's list | 0.0% | 0.5% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Mirae Asset Nifty 500 Healthcare ETF | Nippon India Pharma |
|---|---|---|
| Pharmaceuticals & Biotechnology | 77.8% | 74.0% |
| Healthcare Services | 21.7% | 20.3% |
| Retailing | 0.0% | 2.5% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Mirae Asset Nifty 500 Healthcare ETF vs Nippon India Pharma: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Mirae Asset Nifty 500 Healthcare ETF | Nippon India Pharma Fund |
|---|---|---|
| Total expense ratio (Direct) | Not available | 0.99% |
| Base expense ratio (Direct) | 0.00% | 0.79% |
| Total expense ratio (Regular) | Not available | 1.85% |
| Base expense ratio (Regular) | 0.16% | 1.52% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Mirae Asset Nifty 500 Healthcare ETF vs Nippon India Pharma Fund: Frequently Asked Questions
What is the difference between Mirae Asset Nifty 500 Healthcare ETF and Nippon India Pharma Fund?
Mirae Asset Nifty 500 Healthcare ETF is an ETF fund, Nippon India Pharma Fund is a Sectoral fund, run by Mirae Asset Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 61.2%. Mirae Asset Nifty 500 Healthcare ETF charges 0.35% a year and Nippon India Pharma Fund 0.99%.
Which has the lower expense ratio, Mirae Asset Nifty 500 Healthcare ETF or Nippon India Pharma Fund?
Mirae Asset Nifty 500 Healthcare ETF charges less: 0.35% a year against 0.99%. These are the total expense ratios reported to AMFI.
How much do Mirae Asset Nifty 500 Healthcare ETF and Nippon India Pharma Fund overlap?
61.2%. They hold 26 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, CIPLA. From each fund's latest monthly portfolio.
Which is riskier, Mirae Asset Nifty 500 Healthcare ETF or Nippon India Pharma Fund?
On SEBI's riskometer, Mirae Asset Nifty 500 Healthcare ETF is rated Very High and Nippon India Pharma Fund Very High. Over their common history, the standard deviation of daily returns was 14.16% and 15.19% a year.
Can I invest in both Mirae Asset Nifty 500 Healthcare ETF and Nippon India Pharma Fund?
Yes. 61.2% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Mirae Asset Nifty 500 Healthcare ETF and Nippon India Pharma Fund?
Mirae Asset Nifty 500 Healthcare ETF: Ekta Gala, amp, Ritesh Patel. Nippon India Pharma Fund: Sailesh Raj Bhan.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.